Interesting market-facing updates on progress with Orexin receptor 2 (OXR2) agonists
Two parties involved in research & clinical trials into targeted treatments for narcolepsy and idiopathic hypersomnia made announcements on progress and timelines last week.
Its still far too early to be able to indicate when, if the work is successful, we will see Medicines & Healthcare products Regulatory Agency (MHRA) & National Institute for Health & Care Excellence (NICE) approved Orexin agonists available across all the national health services in the UK, but this is the target that Narcolepsy UK will be working towards on behalf of all those with narcolepsy and idiopathic hypersomnia across the UK.
https://www.takeda.com/newsroom/newsreleases/2025/oveporexton-phase2b-trial-results/
Matt O’Neill
20th May 2025